Psychedelic-assisted therapy and research — psilocybin, MDMA, ketamine, and emerging psychoplastogens in psychiatry.
Key Updates Biomarker-Stratified Antidepressant ResponseA randomized trial in JAMA Psychiatry (Sept 2025) found that patients with treatment-resistant depression who carried the ANK3 biomarker had improved outcomes with liafensine,…
From Psychedelics to Mechanism-Driven Precision: Recent Shifts in Depression Treatment What if we could reliably predict which antidepressant will work for a patient before waiting four weeks of…
An international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report ‘set and…
A Phase 3 clinical trial of COMP360, a synthetic formulation of psilocybin, showed a significant reduction in symptoms of treatment-resistant depression. Conducted at 32 sites across the U.S.…
It is known that psychedelics activate serotonin 2A receptors, which eventually leads to states like increased empathy and out-of-body experiences. One of the key questions remaining n psychedelic…
MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase…
